Cell biologists have
known about genomic loops for decades, but were not previously able to examine them with the level of molecular resolution and detail that is possible now.
Not exact matches
And then you add in what we've been able to do around primary healthcare and the discovery that we can act early in your life
knowing genomics,
knowing the profile of what you have,
knowing things
about your neighborhood and your environment.
Advances in
genomics and bioinformatics mean we now
know a lot
about the relationships among species and their origins, but surprisingly little is
known about which environmental conditions that allows species to multiply.
«There are a lot of things
about very basic
genomics that nobody
knows the answer to yet,» Venter says.
Over the past 20 years the public has been repeatedly told that these big
genomic projects — starting with the Human Genome Project and going on through various other projects — were going to explain everything we needed to
know about the «book of life.»
On the way to finding that out, what's the use of
knowing anything
about cancer
genomics?
You may
know me as the author of MassGenomics, a blog
about next - gen sequencing, genetics, and
genomics that I ran 2008 - 2018.
We
know a great deal
about the
genomic mechanisms through which androgens and estrogens influence behavior; by turning genes on and off and thus affecting levels of proteins in cells, they slowly sculpt the brain circuits and peripheral structures required to produce social output.
Although there is some evidence for the variable distribution of
genomic islands in B. pseudomallei isolates, little is
known about the extent of variation between related strains or their association with disease or environmental survival.
For example, the biologist James Shapiro (no relation) discovered a cellular mechanism of
genomic change that Darwin did not
know about.
According to some experts, «few applicants would move into or out of standard risk pools because
genomic information
about currently
known common variants seldom substantially affects mortality risk estimation already based on phenotype and family history,» and «there is at present insufficient benefit to warrant the addition of predictive
genomic data to actuarial risk stratification models.»
The medical benefits of
genomics go disproportionately to white people, while people of other ethnicities are more likely to receive inconclusive results because scientists don't
know enough
about their genetic variation.